SLDB

Solid Biosciences Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000

$6.20Close $489.6MMarket cap $3.93 – $11.1552-week range Nov 2, 2026Next report

Highlights

Cautions

Not in an uptrend 3 of 8 trend conditions
Lagging the market RS 27 · weaker than 73% of stocks over 12 months
Far from its high 44% below its 52-week high
Results soon Nov 2, 2026, in 1 day

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 6, 2026

Off 12-month high 44%

1wk 4.7% price change

1mo 14.2% price change

12-month return 17% market up 11% · its own up 2%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 2.7× price / book

Earnings yield 41.7% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 110% return on equity

Free cash margin — -$157.4M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 7.2% $0.45 a day · 2×ATR $5.31

RS 27 / 99 vs the universe

Trend 3 / 8 trend template

Relative volume 0.7× vs 50-day average

Up/down volume 0.83 50 sessions

Implied move — no option chain · report Nov 2, 2026

Trend template · 3 of 8

Price above the 150 and 200-day averages: fails
150-day average above the 200-day: passes
200-day average rising for a month: passes
50-day average above the 150 and 200-day: fails
Price above the 50-day average: fails
At least 30% above the 52-week low: passes
Within 25% of the 52-week high: fails
RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 95.1% over the year, from 40m to 79m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Mar 6, 2026

Last shock Oct 13, 2026-13% in one session2.6× volumeno filing matched+7% since

Financials

6 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$174.3M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$157.4M

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Net
Free cash

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 78.97m -7.0% since FY2020

	FY2020Dec 31, 2020	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$0	$13.6M	$8.1M	—	—	—
Operating income	-$88.4M	-$72.3M	-$106.5M	-$104.3M	-$129.7M	-$179.2M
Net income	-$88.3M	-$72.2M	-$86.0M	-$96.0M	-$124.7M	-$174.3M
Net margin	—	-530%	-1062%	—	—	—
Earnings per share	-$25.50	-$10.14	-$10.10	-$4.83	-$3.06	-$1.99
Free cash flow	-$57.5M	-$79.0M	-$101.0M	-$95.7M	-$100.7M	-$157.4M
Free cash margin	—	-580%	-1248%	—	—	—
Cash	$154.7M	$119.1M	$155.4M	$74.0M	$80.2M	$59.9M
Shareholders' equity	$132.1M	$208.2M	$211.7M	$126.5M	$137.2M	$180.0M
Shares outstanding	84.89m	7.36m	19.56m	20.39m	40.47m	78.97m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 6, 2026	Quarterly ↗	Jun 30, 2026	37d
May 12, 2026	Quarterly ↗	Mar 31, 2026	42d
Mar 19, 2026	Annual ↗	Dec 31, 2025	78d
Nov 3, 2025	Quarterly ↗	Sep 30, 2025	34d
Aug 12, 2025	Quarterly ↗	Jun 30, 2025	43d
May 15, 2025	Quarterly ↗	Mar 31, 2025	45d
Mar 6, 2025	Annual ↗	Dec 31, 2024	65d
Nov 6, 2024	Quarterly ↗	Sep 30, 2024	37d
Aug 13, 2024	Quarterly ↗	Jun 30, 2024	44d
May 15, 2024	Quarterly ↗	Mar 31, 2024	45d
Mar 13, 2024	Annual ↗	Dec 31, 2023	73d
Nov 8, 2023	Quarterly ↗	Sep 30, 2023	39d

Current reports

Filed	Disclosed
Aug 6, 2026	Other events ↗
Jun 10, 2026	Shareholder vote ↗
Apr 10, 2026	Director or officer change ↗
Mar 12, 2026	Regulation FD · Other events ↗
Mar 6, 2026	Material agreement · Results · Unregistered share sale · Other events ↗
Nov 3, 2025	Results · Regulation FD · Other events ↗
Jun 13, 2025	Director or officer change · Shareholder vote ↗
May 15, 2025	Other events ↗
Feb 18, 2025	Material agreement · Other events ↗
Feb 18, 2025	Other events ↗
Feb 18, 2025	Results · Other events ↗
Jun 11, 2024	Director or officer change · Shareholder vote ↗